Table 1.
Baseline (first calendar quarter) data of 9269 erythropoietin-stimulating agent–treated peritoneal dialysis patients subdivided based on race and gender
| Entire Cohort | African-American Men | Non-African American Men | African-American Women | Non-African American Women | |
|---|---|---|---|---|---|
| (n = 9269) | (n = 912) | (n = 3935) | (n = 1097) | (n = 3264) | |
| Age (years) | 55 ± 16 | 49 ± 15 | 57 ± 16 | 51 ± 15 | 54 ± 16 |
| Diabetes (%) | 46 | 43 | 49 | 42 | 44 |
| Vintage category (%) | |||||
| <6 months | 65 | 58 | 68 | 57 | 66 |
| 6 to 24 months | 16 | 15 | 17 | 17 | 15 |
| 2 to 5 years | 13 | 17 | 10 | 17 | 13 |
| >5 years | 6 | 10 | 5 | 9 | 6 |
| Primary insurance: Medicare (%) | 58 | 54 | 58 | 59 | 59 |
| Marital status: married (%) | 60 | 58 | 71 | 35 | 56 |
| Presence of ischemic heart disease (%) | 14 | 8 | 20 | 8 | 11 |
| Presence of congestive heart failure (%) | 17 | 14 | 20 | 15 | 15 |
| Presence of history of cardiac arrest (%) | 0.5 | 0.4 | 0.5 | 0.2 | 0.5 |
| Presence of history of myocardial infarction (%) | 6 | 3 | 8 | 3 | 4 |
| Presence of pericarditis (%) | 0.6 | 0.4 | 0.4 | 0.9 | 0.7 |
| Presence of cardiac dysrhythmia (%) | 3.2 | 1.8 | 4.5 | 1.3 | 2.6 |
| Presence of cerebrovascular events (%) | 4.6 | 4.1 | 5.5 | 2.4 | 4.6 |
| Presence of peripheral vascular disease (%) | 8.3 | 5.2 | 10.7 | 4.8 | 7.4 |
| Presence of chronic obstructive pulmonary disease (%) | 3.5 | 1.7 | 4.3 | 2.0 | 3.6 |
| Presence of cancer (%) | 3.5 | 1.9 | 4.1 | 2.3 | 3.5 |
| Body mass index (kg/m2) | 27.0 ± 7.2 | 25.4 ± 4.9 | 25.7 ± 7.7 | 28.3 ± 6.0 | 28.5 ± 7.1 |
| Serum albumin (g/dl) | 3.6 ± 0.5 | 3.6 ± 0.5 | 3.6 ± 0.5 | 3.5 ± 0.5 | 3.4 ± 0.5 |
| Serum creatinine (mg/dl) | 8.4 ± 3.9 | 11.4 ± 4.8 | 8.4 ± 3.7 | 9.5 ± 4.0 | 7.3 ± 3.1 |
| Serum ferritin (ng/ml) | 364 ± 422 | 403 ± 422 | 347 ± 345 | 424 ± 656 | 352 ± 403 |
| Total iron-binding capacity (mg/dl) | 240 ± 50 | 227 ± 48 | 244 ± 48 | 226 ± 48 | 244 ± 53 |
| Serum bicarbonate (mEq/L) | 25 ± 3 | 25 ± 3 | 25 ± 3 | 25 ± 3 | 25 ± 3 |
| Serum phosphorus (mg/dl) | 5.3 ± 1.4 | 5.4 ± 1.5 | 5.3 ± 1.5 | 5.3 ± 1.4 | 5.3 ± 1.4 |
| Serum calcium (mg/dl) | 9.2 ± 0.8 | 9.1 ± 0.8 | 9.1 ± 0.8 | 9.2 ± 0.8 | 9.3 ± 0.8 |
| Hemoglobin (g/dl) | 12.1 ± 1.5 | 12.0 ± 1.6 | 12.3 ± 1.5 | 11.7 ± 1.6 | 12.1 ± 1.5 |
| White blood cell count (×103/μl) | 7.6 ± 2.6 | 6.7 ± 2.4 | 7.7 ± 2.7 | 7.1 ± 2.4 | 7.9 ± 2.5 |
| Lymphocyte (% of total white blood cell count) | 19 ± 8 | 23 ± 8 | 18 ± 7 | 23 ± 8 | 19 ± 7 |
| Erythropoietin stimulating agent dose (units per week) | 7998 ± 8410 | 8218 ± 7549 | 7685 ± 8592 | 8695 ± 7938 | 8024 ± 7313 |
9208 patients have information for race and gender. Mean values are presented as the means ± SDs.